These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

183 related items for PubMed ID: 39305222

  • 1. Ten-day vonoprazan-based versus fourteen-day proton pump inhibitor-based therapy for first-line Helicobacter pylori eradication in China: A meta-analysis of randomized controlled trials.
    Gao W, Wang Q, Zhang X, Wang L.
    Int J Immunopathol Pharmacol; 2024; 38():3946320241286866. PubMed ID: 39305222
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Vonoprazan-based therapies versus PPI-based therapies in patients with H. pylori infection: Systematic review and meta-analyses of randomized controlled trials.
    Liu L, Shi H, Shi Y, Wang A, Guo N, Li F, Nahata MC.
    Helicobacter; 2024; 29(3):e13094. PubMed ID: 38790090
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and Safety of Vonoprazan-Based versus Proton Pump Inhibitor-Based Triple Therapy for Helicobacter pylori Eradication: A Meta-Analysis of Randomized Clinical Trials.
    Lyu QJ, Pu QH, Zhong XF, Zhang J.
    Biomed Res Int; 2019; 2019():9781212. PubMed ID: 31211144
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Vonoprazan-amoxicillin dual therapy for Helicobacter pylori eradication in Chinese population: A prospective, multicenter, randomized, two-stage study.
    Huang XP, Liu YJ, Lin SW, Shao YF, Qiu F, Qiu QW, Xu ZK, Chen JX, Chen LH, Lin ZQ, Dai WH, Zhang MQ, Jiang Q, Xiao ZQ, Cheng XX, Zhang XF, You WB, Chen W, Li LQ, Lin WX, Wang YF, Lai FJ, Chen LQ, Huang ZH, Zheng WQ, Wei JQ, Lin ZH.
    World J Gastroenterol; 2024 Jul 21; 30(27):3304-3313. PubMed ID: 39086752
    [Abstract] [Full Text] [Related]

  • 13. Low-dose or high-dose amoxicillin in vonoprazan-based dual therapy for Helicobacter pylori eradication? A systematic review and meta-analysis.
    Ju KP, Kong QZ, Li YY, Li YQ.
    Helicobacter; 2024 Jul 21; 29(1):e13054. PubMed ID: 38900537
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Vonoprazan-based triple therapy is non-inferior to susceptibility-guided proton pump inhibitor-based triple therapy for Helicobacter pylori eradication.
    Tanabe H, Yoshino K, Ando K, Nomura Y, Ohta K, Satoh K, Ichiishi E, Ishizuka A, Otake T, Kohgo Y, Fujiya M, Okumura T.
    Ann Clin Microbiol Antimicrob; 2018 Jun 28; 17(1):29. PubMed ID: 29950163
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Efficacy and Safety of Vonoprazan-Amoxicillin Dual Regimen With Varying Dose and Duration for Helicobacter pylori Eradication: A Multicenter, Prospective, Randomized Study.
    Peng X, Yao JY, Ma YQ, Li GH, Chen HW, Wan Y, Liang DS, Zhang M, Zhi M.
    Clin Gastroenterol Hepatol; 2024 Jun 28; 22(6):1210-1216. PubMed ID: 38309492
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Treatment of Helicobacter pylori with potassium competitive acid blockers: A systematic review and meta-analysis.
    Kanu JE, Soldera J.
    World J Gastroenterol; 2024 Mar 07; 30(9):1213-1223. PubMed ID: 38577188
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.